Search Result

Results for "

NFKB1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (2) Akt (1) AMPK (2) Apoptosis (6) ASK1 (2) Autophagy (2) Bacterial (1) Caspase (1) COX (3) CX3CR1 (2) E1/E2/E3 Enzyme (1) Endogenous Metabolite (1) HMG Family (2) HSV (2) IRE1 (1) JNK (3) Keap1-Nrf2 (2) MAP3K (1) MMP (2) Molecular Glues (1) mRNA (1) NF-κB (15) NOD-like Receptor (NLR) (4) PCSK9 (2) Reactive Oxygen Species (ROS) (3) Reference Standards (2) Sirtuin (1) Small Interfering RNA (siRNA) (3) SOD (2) TNF Receptor (2) Toll-like Receptor (TLR) (2) VEGFR (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (4) Endocrinology (2) Infection (2) Inflammation/Immunology (10) Metabolic Disease (3) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) mRNA (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-49444

EN450	NF-κB Molecular Glues E1/E2/E3 Enzyme	Cancer
EN450 is a cysteine-reactive covalent molecular glue degrader targeting *NF-κB. EN450 interacts with allosteric C111 in the E2 ubiquitin ligase UBE2D. EN450 induces the ternary complex formation between UBE2D and NFKB1. EN450 exerts its anti-proliferative effects through a Cullin E3 ligase* and proteasome-dependent mechanism ^[1].

HY-133987

AP-1/NF-κB activation inhibitor 1 3 Publications Verification	NF-κB	Inflammation/Immunology
AP-1/NF-κB activation inhibitor 1 is a potent *AP-1* and *NF-κB* mediated transcriptional activation inhibitor (IC₅₀=1 μM), without blocking basal transcription driven by the β-actin promoter. AP-1/NF-κB activation inhibitor 1 has a similar inhibitory effect on the production of IL-2 and IL-8 levels in stimulated cells ^[1].

HY-152177

JS6	NF-κB	Cancer
JS6 is a Bcl3 inhibitor, and inhibits Bcl3-NF-kB1 binding. JS6 inhibits tumor cell growth in vitro and in vivo ^[1].

HY-N3532

Cannabisin F	Sirtuin	Neurological Disease Inflammation/Immunology
Cannabisin F is a *SIRT1* modulator. Cannabisin F, as a hempseed lignanamide, can be used for the research of anti-inflammatory and anti-oxidative. Cannabisin F may be a potential agent of neurodegenerative diseases as modulators of SIRT1/NF-κB and Nrf2 ^[1].

HY-RS09255

Nfkb1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) NF-κB	Others
Nfkb1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nfkb1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nfkb1 Mouse Pre-designed siRNA Set A Nfkb1 Mouse Pre-designed siRNA Set A

HY-RS09254

NFKB1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NFKB1 Human Pre-designed siRNA Set A contains three designed siRNAs for NFKB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NFKB1 Human Pre-designed siRNA Set A NFKB1 Human Pre-designed siRNA Set A

HY-RS09256

Nfkb1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) NF-κB	Others
Nfkb1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nfkb1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nfkb1 Rat Pre-designed siRNA Set A Nfkb1 Rat Pre-designed siRNA Set A

HY-174569

*Human NFKB1* mRNA**	mRNA	Inflammation/Immunology
Human NFKB1 mRNA encodes the human nuclear factor kappa B subunit 1 (NFKB1) protein, a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. NFKB is a critical regulator of the immediate-early response to viral infection.

HY-N15315

Triptriolide	Apoptosis MAP3K NF-κB	Others
Triptriolide inhibits Puromycin aminonucleoside PAN (HY-15695)-induced apoptosis in mouse podocytes through regulation of Bcl-2 family proteins and inhibition of Caspase-3. Triptriolide promotes the cell survival, protects and restores the podocyte function through activation of *TAK1-NF-κB* signaling pathway and upregulation of podocin ^[1].

HY-W995241

BPD	COX NF-κB	Inflammation/Immunology
BPD is a COX-2 and *TAK1-NF-κB* inhibitor, with an IC₅₀ of 18.5 μM for COX-2. BPD inhibits the expression of iNOS, TNF-α, IL-6 and IL-1β at the transcriptional level. BPD has anti-inflammatory activity. BPD can inhibit Carrageenan-induced paw oedema and LPS-induced septic death ^[1].

HY-174138

NF-κB degrader 1	NF-κB	Inflammation/Immunology
NF-κB degrader 1 (Compound MD-1) is a *NF-κB1* p105 subunit degrader. NF-κB degrader 1 shows anti-inflammatory activity (IC₅₀ for inhibiting TNF-α is 2.02 μM, and for inhibiting NO is 5.40 μM). NF-κB degrader 1 induces p105 degradation dependent on the Cullin-RING ligase (CRL) SCFBTCP, suppressing NF-κB transcriptional activity. NF-κB degrader 1 is promising for research of inflammation-related diseases ^[1].

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates *Nrf2/HO-1, HMGB1/NF-κB* and *Fractalkine/CX3CR1*. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation ^[1] .

HY-19696B

Tauroursodeoxycholate dihydrate Maximum Cited Publications 87 Publications Verification Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate	Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, *IRE1α/TRAF2/NF-κB, prevents JNK* phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease ^[1] .

HY-N1508

Ecliptasaponin A	MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating *ASK1/JNK* pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the *HMGB1/TLR4/NF-κB* pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of *ESR1* receptors ^[1] .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates *Nrf2/HO-1, HMGB1/NF-κB* and *Fractalkine/CX3CR1*. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation ^[1] .

HY-N1508R

Ecliptasaponin A (Standard)	Reference Standards MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ecliptasaponin A (Standard) is the analytical standard for Ecliptasaponin A (HY-N1508). Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating *ASK1/JNK* pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the *HMGB1/TLR4/NF-κB* pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of *ESR1* receptors.

HY-N0772

Isomangiferin 2 Publications Verification	VEGFR NOD-like Receptor (NLR) NF-κB Bacterial AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV	Infection Metabolic Disease Inflammation/Immunology Cancer
Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the *HMGB1/NLRP3/NF-κB* signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing ^[1] .

HY-N0772R

Isomangiferin (Standard)	Reference Standards VEGFR NF-κB NOD-like Receptor (NLR) AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV	Infection Metabolic Disease Inflammation/Immunology Cancer
Isomangiferin (Standard) is the analytical standard of Isomangiferin (HY-N0772). This product is intended for research and analytical applications. Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the *HMGB1/NLRP3/NF-κB* signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing.

Cat. No.	Product Name

HY-L014

NF-κB Signaling Compound Library	1,385 compounds
Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. MCE owns a unique collection of 1,385 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

NF-κB Signaling Compound Library

1,385 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 1,385 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates *Nrf2/HO-1, HMGB1/NF-κB* and *Fractalkine/CX3CR1*. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation ^[1] .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates *Nrf2/HO-1, HMGB1/NF-κB* and *Fractalkine/CX3CR1*. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3532

Cannabisin F	Monophenols Source classification Phenols Solanaceae Plants Datura metel Linn.	Sirtuin
Cannabisin F is a *SIRT1* modulator. Cannabisin F, as a hempseed lignanamide, can be used for the research of anti-inflammatory and anti-oxidative. Cannabisin F may be a potential agent of neurodegenerative diseases as modulators of SIRT1/NF-κB and Nrf2 ^[1].

HY-19696B

Tauroursodeoxycholate dihydrate 85+ Cited Publications Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate	Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt
Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, *IRE1α/TRAF2/NF-κB, prevents JNK* phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease ^[1] .

HY-N1508

Ecliptasaponin A	Triterpenes other families Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields	MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating *ASK1/JNK* pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the *HMGB1/TLR4/NF-κB* pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of *ESR1* receptors ^[1] .

HY-N0772

Isomangiferin 2 Publications Verification	Infection Liliaceae Xanthones Classification of Application Fields Source classification Phenols Polyphenols Anemarrhena asphodeloides Bunge Plants Disease Research Fields	VEGFR NOD-like Receptor (NLR) NF-κB Bacterial AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV
Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the *HMGB1/NLRP3/NF-κB* signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing ^[1] .

HY-N15315

Triptriolide	Triterpenes Terpenoids Source classification Celastraceae Tripterygium wilfordii Hook. f. Plants	Apoptosis MAP3K NF-κB
Triptriolide inhibits Puromycin aminonucleoside PAN (HY-15695)-induced apoptosis in mouse podocytes through regulation of Bcl-2 family proteins and inhibition of Caspase-3. Triptriolide promotes the cell survival, protects and restores the podocyte function through activation of *TAK1-NF-κB* signaling pathway and upregulation of podocin ^[1].

HY-N1508R

Ecliptasaponin A (Standard)	Triterpenes other families Terpenoids Source classification Plants	Reference Standards MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK
Ecliptasaponin A (Standard) is the analytical standard for Ecliptasaponin A (HY-N1508). Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating *ASK1/JNK* pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the *HMGB1/TLR4/NF-κB* pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of *ESR1* receptors.

HY-N0772R

Isomangiferin (Standard)	Liliaceae Xanthones Source classification Phenols Polyphenols Anemarrhena asphodeloides Bunge Plants	Reference Standards VEGFR NF-κB NOD-like Receptor (NLR) AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV
Isomangiferin (Standard) is the analytical standard of Isomangiferin (HY-N0772). This product is intended for research and analytical applications. Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective VEGFR-2 kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the *HMGB1/NLRP3/NF-κB* signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing.

Cat. No.	Compare	Product Name	Species	Source

HY-P71124

	NFKB1 Protein, Human (His) DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	Human	E. coli
	The NFKB1 protein is a subunit of NF-kappa-B and regulates transcription in a variety of biological processes. It forms homodimeric or heterodimeric complexes with RELA/p65, RELB, and NFKB2/p52. NFKB1 Protein, Human (His) is the recombinant human-derived NFKB1 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80764

	NF-KB p105/p50 Antibody (YA700) NFKB1; Nuclear factor NF-kappa-B p105 subunit; DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	WB	Human, Mouse, Rat
	NF-KB p105/p50 Antibody (YA700) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to NF-KB p105/p50.

HY-P86373

	NF-κB1 p105/p50 Antibody (YA6065) NFKB1; Nuclear factor NF-kappa-B p105 subunit; DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	NF-κB1 p105/p50 Antibody (YA6065) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NF-κB1 p105/p50.

HY-P80244

	NF-KB p105/p50 Antibody (YA699) DKFZp686C01211 antibody; DNA binding factor KBF1 antibody; DNA binding factor KBF1 EBP1 antibody; DNA-binding factor KBF1 antibody; EBP 1 antibody; EBP-1 antibody; EBP1 antibody; KBF1 antibody; MGC54151 antibody; NF kappa B antibody; NF kappaB antibody; NF kappabeta antibody; NF kB1 antibody; NFkappaB antibody; NFKB 1 antibody; NFKB p105 antibody; NFKB p50 antibody; NFKB1 antibody; NFKB1_HUMAN antibody; Nuclear factor kappa B DNA binding subunit antibody; Nuclear factor kappa-B, subunit 1 antibody; Nuclear factor NF kappa B p105 subunit antibody; Nuclear factor NF kappa B p50 subunit antibody; Nuclear factor NF-kappa-B p50 subunit antibody; Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody; p105 antibody; p50 antibody; p84/NF-kappa-B1 p98 antibody; Transcription factor NFKB1 antibody;	WB, ICC/IF, IHC-P	Human, Mouse
	NF-KB p105/p50 Antibody (YA699) is a Mouse-derived and non-conjugated IgM monoclonal antibody, targeting to NF-KB p105/p50.

HY-P81049

	Phospho-NF-KB p105/p50(Ser337) Antibody NFKB1; NF-KB; Nuclear factor NF-kappa-B p105 subunit; DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; Nuclear factor NF-kappa-B p50 subunit; NFKB p105 / p50; NFKB p105/p50; nuclear factor kappa B subunit 1; NF-kB; CVID12; NF-kB1; NFKB-p50; NFkappaB; NF-kappaB; NFKB-p105; NF-kappa-B1; NF-kappabeta;	WB, IHC-P, IHC-F, FC, ICC/IF, ELISA	Human, Mouse
	Phospho-NF-KB p105/p50(Ser337) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-NF-KB p105/p50(Ser337).

HY-P85639

	NF-KB p105/p50 Antibody (YA5331) DKFZp686C01211; DNA binding factor KBF1; DNA binding factor KBF1 EBP1; DNA-binding factor KBF1; EBP 1; EBP-1; EBP1; KBF1; MGC54151; NF kappa B; NF kappaB; NF kappabeta; NF kB1; NFkappaB; NFKB 1; NFKB p105; NFKB p50; NFKB1; NFKB1_HUMAN; Nuclear factor kappa B DNA binding subunit; Nuclear factor kappa-B, subunit 1; Nuclear factor NF kappa B p105 subunit; Nuclear factor NF kappa B p50 subunit; Nuclear factor NF-kappa-B p50 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; p105; p50; p84/NF-kappa-B1 p98.	WB	Human
	NF-KB p105/p50 Antibody (YA5331) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to NF-KB p105/p50.